Skip to main content

Eva Colas Ortega

I am principal researcher in the Group of Biomedical Research in Gynecology, where I lead the translational research group. My research interest is to provide solutions for unmet clinical needs in gynecology, mainly in endometrial cancer and endometriosis. We work on biomarker research to provide with innovative solutions and preclinical models to improve personalized medicine.

Institutions of which they are part

Head of group
Biomedical Research in Gynaecology
Vall Hebron Institut de Recerca

Eva Colas Ortega

Institutions of which they are part

Head of group
Biomedical Research in Gynaecology
Vall Hebron Institut de Recerca

I am principal researcher in the Group of Biomedical Research in Gynecology, where I lead the translational research group. My research interest is to provide solutions for unmet clinical needs in gynecology, mainly in endometrial cancer and endometriosis. We work on biomarker research to provide with innovative solutions and preclinical models to improve personalized medicine.

I am biologist by formation and fully dedicated to endometrial cancer research for the last 16 years. From 2017, I lead my own team in the Group of Biomedical Research in Gynecology (VHIR) and my research focus on the implementation of molecular diagnostics and personalized medicine in gynecology, mainly in endometrial cancer (EC) and endometriosis.
In my career I participated in the development of the first EC patient-derived murine models (PDX), and today, my group owns one of the largest PDX biobanks in Europe, which is used by us, partners and pharma to assess treatments for EC patients. Importantly, I have also grown as a scientist dedicated to biomarker research in gynecological fluids. I worked in the development of the first molecular kit to diagnose EC. Today, I am the European Coordinator of a multicenter study to develop a non-invasive diagnosis of EC (ERA PerMed), and am the founder of a spin-off (MiMARK Diagnostics S.L.) that aims to develop innovative solutions for women health.
As a summary, I have a total of 73 scientific articles with impact factor; 17 of them as senior author; and am inventor of 4 patents. My scientific and leadership capacity is proved by the supervision of 12 doctoral theses, 6 of which have already been defended, two of them awarded. I have participated in 32 competitive research projects, being 13 of them principal investigator, and I am actively participating in national (CIBERONC) and international (ENITEC) cancer networks.
I have been teaching in graduate and master studies for the last 7 years; and I have been on the Steering Committee of the Societat Catalana de Biologia for 10 years.

Projects

WomEC, desenvolupament d'una eina molecular per la millora del diagnòstic en càncer d'endometri.

IP: Eva Colas Ortega
Collaborators: Antonio Gil Moreno, Miriam Izquierdo Sans, Francisco Javier Carvajal Rodriguez
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 33960
Reference: AGAUR/DI2022_1/GIL
Duration: 01/08/2022 - 31/07/2025

ADVANCING ON THE DEVELOPMENT OF A NON-INVASIVE TOOL TO EARLY DIAGNOSE ENDOMETRIAL CANCER

IP: Eva Colas Ortega
Collaborators: Beatriz Villafranca Magdalena, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 119567
Reference: FI21/00271
Duration: 01/01/2022 - 31/12/2025

Cytomark - Desarrollo de un test diagnóstico personalizado y no invasivo de cáncer de endometrio en el fluido cervical

IP: Eva Colas Ortega
Collaborators: Irene De la Calle Fuentes, Antonio Gil Moreno, Carina Masferrer Ferragutcasas, Raquel Delgado Gil, Valeria Tubita
Funding agency: Asociación Española Contra el Cáncer
Funding: 188000
Reference: PERME212443COLA
Duration: 01/01/2022 - 31/01/2026

Cytomark - Desarrollo de un test diagnóstico personalizado y no invasivo de cáncer de endometrio en el fluido cervical

IP: Eva Colas Ortega
Collaborators: Angel García Jiménez, Silvia Cabrera Diaz, Antonio Gil Moreno, Melek Denizli
Funding agency: Instituto de Salud Carlos III
Funding: 110715
Reference: AC21_2/00030
Duration: 01/01/2022 - 31/12/2025

Related news

Researchers from the centre took part in international debates on AI in healthcare, spin-offs emerging from research were presented, and several initiatives linked to VHIR received recognition in the field of entrepreneurship.

The grants promote new therapeutic strategies and diagnostic tools in highly complex tumors such as glioblastoma, triple-negative breast cancer, and endometrial cancer.

The Department of Health of the Generalitat de Catalunya grants subsidies for carrying out validation tests on innovative projects in the field of health that are in the early stages of development.

Related professionals

Lara Grau Lopez

Lara Grau Lopez

Psychiatry, Mental Health and Addictions
Read more
Mayli Lung Suarez

Mayli Lung Suarez

Microbiology
Read more
Silvia Ballester Esteve

Silvia Ballester Esteve

Research technician
Neuroradiology
Read more
Emma Granados Serra

Emma Granados Serra

Unitat legal
Legal Directorate
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.